AML Mutation Analysis Panel
FLT3/IDH1/IDH2
*IF CYTO & FLT3 are Normal, REFLEX TO: CEBPA/NPM1
*IF FLT3(+) with monocytic differentiation, REFLEX TO: NPM1
*IF inv(16) or t(8;21), REFLEX TO: KIT exons 8,17
AML with Monocytosis
inv16/CBFB-break-apart, KMT2A(MLL)-break-apart
AML-M0 (reflex panel)
cy-MPO, cy-CD79a, CD34, CD117, cy-CD3, Near-IR, CD45
AML-M6-M7 (reflex panel)
CD235a, CD41a, CD34, CD61, CD71, Near-IR, HLA-DR, CD45
Amyloid A
Amyloid A reacts with amyloid deposits in tissues. When accompanied by special stain Congo Red, Amyloid A can differentiate between primary and secondary amyloidosis. Because this stains is interpreted in context of Amyloid P and Congo Red, testing options available may differ.
Anaplastic Lymphoma Kinase (Lymphoma)
ALK
Annexin 1
Annexin A1 (ANXA1), a gene related to phagocytosis, is one of the most upregulated genes in hairy cell leukemia. Annexin A1 is strongly expressed on the cell membrane of 97% of hairy cell leukemia cases. Although Annexin A1 is negative in normal B-cells or B-cell tumors other than "classic" hairy cell leukemia, it stains myeloid cells, macrophages, and subsets of benign T-cells.
AR (Androgen Receptor)
Androgen receptor (AR) regulates the growth of the prostate epithelial cells. AR positive cells are more likely to be responsive to hormonal therapy in untreated prostate carcinomas. In patients with hormone refractory prostate carcinoma, the presence of AR has a negative prognostic impact. It is also commonly expressed in salivary duct carcinoma.
Arginase 1
Arginase 1 (ARG1) is a binuclear manganese metalloenzyme expressed in the liver. It is used for the diagnosis of benign and malignant hepatocytes.
ATRX
ATRX mutations commonly occur in grade II/III astrocytoma and secondary glioblastoma multiforme (GBM) brain tumors. ATRX loss in astrocytic tumors is associated with a favorable prognosis.